AKT inhibitor AZD5363 well tolerated, yielded partial response in patients with advanced solid tumors

April 8, 2013, American Association for Cancer Research

The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in humans, and two patients with advanced solid tumors showed partial response, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

"PI3K/AKT signaling is very important in ," said Udai Banerji, M.D., Ph.D., clinical senior lecturer at the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London, United Kingdom. "This signaling pathway is highjacked by abnormalities or in genes that can cause a normal cell to behave like a cancer cell."

AZD5363 is a new-generation drug inhibiting the three forms of the AKT protein: AKT1, AKT2 and AKT3. It has shown promising results in several tumor cell lines and animal studies. In prior clinical trials, AKT inhibitors have almost always been tested in continuous dosing schedules, resulting in excessive toxicity, according to Banerji.

Banerji and colleagues conducted two phase I studies and administered AZD5363 to the patients in two schedules: continuous dosing seven days a week and intermittent dosing with four days on and three days off.

Among the 92 patients recruited thus far, an intermittent dosing schedule of 480 mg twice a day was generally well tolerated. Side effects included , rash and diarrhea. "But what is important about these side effects, such as raised blood sugar, is that these are known consequences of targeting the ," said Banerji. "This provides proof of principle that the drug is working."

Using pharmacokinetics studies, the team determined that the dose achieved in the patients' blood was comparable to the dose used in in which they saw positive outcomes. More than 30 percent reduction was seen in the levels of two proteins, pPRAS40 and pGSK3 beta, in plucked hair and collected from the patients, suggesting that the drug successfully inhibited AKT.

One patient with ovarian cancer and one with cervical cancer showed partial response to treatment. Both had a mutation in either AKT1 or PIK3CA in their cancers. A third patient with ovarian cancer with a PIK3CA mutation had prolonged stable disease.

"What is very gratifying is that a response like this to a single agent is not something we see very often," said Banerji. "Also, these data support the growing realization that AKT inhibitors are beneficial when administered intermittently and not continuously."

Encouraged by these results, AstraZeneca recently initiated two phase Ib studies with patients with prostate and breast cancers. AZD5363 was discovered by AstraZeneca subsequent to collaboration with Astex Therapeutics and its collaboration with The Institute of .

Explore further: Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway

Related Stories

Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway

November 7, 2012
Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several, standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes' pathways ...

Researchers find more clues to causes of breast cancer

October 27, 2011
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component ...

Common genetic alteration found in head and neck cancers may not be key to effective treatment

January 29, 2013
Although a large majority of head and neck cancers have a deregulation of the PI3K/AKT/mTOR pathway, data recently published in Cancer Research, a journal of the American Association for Cancer Research, indicated that deregulation ...

Possible therapy for tamoxifen resistant breast cancer identified

August 30, 2012
(Medical Xpress)—A study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has discovered how tamoxifen-resistant ...

First genome sequencing clinical trial for triple negative cancer points to new treatments

December 8, 2011
Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium.

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

July 20, 2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...

Recommended for you

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Spread of deadly eye cancer halted in cells and animals

November 12, 2018
By comparing genetic sequences in the eye tumors of children whose cancers spread with tumors that didn't spread, Johns Hopkins Medicine researchers report new evidence that a domino effect in cells is responsible for the ...

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.